Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF)

[1]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[2]  K. Swedberg,et al.  Beta-blocking agents in heart failure. Should they be used and how? , 1996, European heart journal.

[3]  J. Cohn,et al.  The management of chronic heart failure. , 1996, The New England journal of medicine.

[4]  M. Pfeffer,et al.  Beta-adrenergic blockers and survival in heart failure. , 1996, The New England journal of medicine.

[5]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[6]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[7]  P. Grayburn,et al.  Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.

[8]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[9]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[10]  P. Held.  Effects of beta blockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects. , 1993, The American journal of cardiology.

[11]  T. Hedner,et al.  Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. , 1991, Journal of the American College of Cardiology.

[12]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[13]  R. Bergstrand,et al.  The Relationship Between Metoprolol Plasma Concentration and Beta1‐Blockade in Healthy Subjects: A Study on Conventional Metoprolol and Metoprolol CR/ZOK Formulations , 1990, Journal of clinical pharmacology.

[14]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[15]  R. Gunnar,et al.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.

[16]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.